CN107669763B - Enteromorpha polysaccharide compound auxiliary blood fat reducing health-care product and preparation method thereof - Google Patents
Enteromorpha polysaccharide compound auxiliary blood fat reducing health-care product and preparation method thereof Download PDFInfo
- Publication number
- CN107669763B CN107669763B CN201711187356.0A CN201711187356A CN107669763B CN 107669763 B CN107669763 B CN 107669763B CN 201711187356 A CN201711187356 A CN 201711187356A CN 107669763 B CN107669763 B CN 107669763B
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- enteromorpha polysaccharide
- blood fat
- enteromorpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Abstract
The invention provides an enteromorpha polysaccharide compound auxiliary blood fat reducing health-care product. The health product is a capsule, a tablet or a granule, and consists of the following raw materials: 50-70 parts of enteromorpha polysaccharide extract, 10-15 parts of kudzu root extract, 5-10 parts of gynostemma pentaphylla extract, 5-10 parts of hawthorn extract and 10-15 parts of red yeast rice enzyme, wherein the parts of the raw materials are in parts by weight. The invention also provides a preparation method of the health product, which comprises the steps of mixing the raw materials in parts by weight, molding, drying, packaging and inspecting to obtain a finished product.
Description
Technical Field
The invention belongs to the field of health care products, and particularly relates to an enteromorpha polysaccharide compound auxiliary blood fat reducing health care product and a preparation method thereof.
Background
Cardiovascular and cerebrovascular diseases are the general names of cardiovascular and cerebrovascular diseases, and generally refer to heart diseases, cerebral thrombosis, cerebral hemorrhage and other diseases caused by hyperlipidemia, blood hyperviscosity, atherosclerosis and hypertension. The number of people dying from cardiovascular and cerebrovascular diseases every year in the world is as high as 1500 thousands of people, and the people live at the first position of various causes of death.
Hyperlipidemia is the cause of repeated increase in blood pressure. Blood is sticky, and the blood flow is obstructed, and blood can only rely on the strength of blood flow, extrudes the blood vessel and can pass through, gives the continuous increase of vascular pressure, has formed hypertension. The blood lipid blockage is serious, and the cerebral thrombosis is directly caused. When the pressure of crowded blood flow is too high, the blood vessels can be burst to cause fatal crisis such as cerebral hemorrhage, stroke and the like.
Enteromorpha (Enteromorpha prolifera, EP), also called "marine green algae" or "green algae", is an algae plant of Enteromorpha of Ulvaceae of Ulvales of the green algae Menispermales, and is used as a natural wild green algae in intertidal zones, has strong natural reproductive capacity and huge yield, and has very high development and utilization values. The polysaccharide is a main active ingredient of enteromorpha, and researches show that the enteromorpha polysaccharide has the efficacy of reducing blood fat at present.
In addition, researches show that the hawthorn, the lotus leaf, the tea and the like all contain active ingredients with the functions of reducing blood fat and resisting oxidation, and the compound enteromorpha polysaccharide prepared from the raw materials and the enteromorpha polysaccharide is expected to reduce the consumption of the enteromorpha polysaccharide and the cost of the raw materials and simultaneously has the possibility of playing the synergistic effect of multiple targets and multiple ingredients in the aspect of reducing blood fat.
In 2015, a scientific and technological document named 'research on lipid-lowering and lipid peroxidation-resisting effects of compound enteromorpha polysaccharide' is published in university of Dalian medical science by Chen Jie and Linvingting, and a compound enteromorpha polysaccharide (prepared from 25% of enteromorpha polysaccharide, hawthorn extract, lotus leaf extract and tea polyphenol) is published in the scientific and technological document, a rat fed with high-fat feed is taken as a living body, the compound enteromorpha polysaccharide is subjected to gastric perfusion intervention for 45d, and the determination finds that: compared with rats not perfused with the compound enteromorpha polysaccharide, the serum of the rats perfused with the compound enteromorpha polysaccharide has reduced Total Cholesterol (TC), Triglyceride (TG) and low density lipoprotein cholesterol (LDL-C); while high density lipoprotein cholesterol (HDL-C) is elevated, it is believed that: the compound Enteromorpha polysaccharide has the function of reducing blood lipid.
In fact, the authors of the above, chenjie and linvingting, belong to the cooperative developers of the present inventors, and the present inventors also sent the compound enteromorpha polysaccharide product prepared according to the above compound enteromorpha polysaccharide formula to the centers of fujiangprovince for disease control and prevention to perform animal experiments in early days, and the determination results were: compared with rats not perfused with the compound enteromorpha polysaccharide, the Total Cholesterol (TC), Triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) in the serum of the rats perfused with the compound enteromorpha polysaccharide have no obvious change; while high density lipoprotein cholesterol (HDL-C) was increased, but the increase was small (see table 1 below for details). Therefore, the centers for prevention and treatment of diseases in Fujian province give the following conclusions: according to the judgment standard in the evaluation method of the auxiliary blood fat reducing function (State food and drug administration [2012] 107), the product is considered not to have the function of auxiliary blood fat reduction. In addition, the product is also informed by workers of the Shandong province disease prevention control center: the difference between the rat and the human body is large, the rat and the human body are clinically responsible for the life of a patient, and the enteromorpha polysaccharide in the formula of the compound enteromorpha polysaccharide is cool, only the hawthorn is warm, and the warm-nature neutralization and cooling effects of the hawthorn are very limited, so that the compound enteromorpha polysaccharide is obviously too cool, has large stimulation to the digestive system of a subject and obvious side effect, and cannot be used for normal human body tests. In addition, in fact, even products having an auxiliary hypolipidemic effect through animal tests often do not have an auxiliary hypolipidemic effect when used in clinical tests because: in the animal test, a rat fed with a high fat diet for a short period is used as a subject, which is actually only short-term hyperlipemia and is liable to lower the blood lipid index, whereas natural persons suffering from diabetes or hyperlipemia are long-term hyperlipemia and are not liable to lower the blood lipid index.
Table 1. influence of existing compound Enteromorpha polysaccharide product on rat blood fat (mmol/L, n is 10)
Disclosure of Invention
The invention aims to provide an enteromorpha polysaccharide compound auxiliary blood fat reducing health-care product.
An enteromorpha polysaccharide compound auxiliary blood fat reducing health care product is a capsule, a tablet or a granule, and consists of the following raw materials: 50-70 parts of enteromorpha polysaccharide extract, 10-15 parts of kudzu root extract, 5-10 parts of gynostemma pentaphylla extract, 5-10 parts of hawthorn extract and 10-15 parts of red yeast rice enzyme, wherein the parts of the raw materials are in parts by weight.
The second purpose of the invention is to provide a preparation method of the health care product.
A preparation method of an enteromorpha polysaccharide compound health product for assisting in reducing blood fat comprises the following steps:
(1) respectively weighing 50-70 parts of enteromorpha polysaccharide extract, 10-15 parts of kudzu root extract, 5-10 parts of gynostemma pentaphylla extract, 5-10 parts of hawthorn extract and 10-15 parts of red yeast enzyme, and mixing to obtain a mixed raw material;
(2) and (4) forming, drying, packaging and inspecting the mixed raw materials to obtain a finished product.
The enteromorpha polysaccharide extract, the pueraria extract, the gynostemma pentaphylla extract, the hawthorn extract and the monascus enzyme are organically combined for the first time, the comprehensive consideration is given to the treatment range, the requirements of the illness state are met, simultaneously, the intensity and the toxicity of the medicines are monitored, and the adverse factors possibly caused to the human body are eliminated. The radix puerariae extract, the hawthorn extract and the red yeast enzyme are warm, so that the cold property of the enteromorpha polysaccharide extract is effectively neutralized, the stimulation to a digestive system is effectively reduced, and the intestinal absorption is enhanced. The enteromorpha polysaccharide has a large molecular weight, is not easy to be absorbed by intestinal tracts of patients with hyperlipidemia, and the absorption rate of the enteromorpha polysaccharide is improved by using red yeast enzyme (active biological bacteria extracted by fermentation), so that complementary advantages are increased. In addition, the content of potassium element in the enteromorpha polysaccharide reaches 3.99 percent, the excretion of sodium can be promoted, the blood vessel can be well protected, and meanwhile, the enteromorpha polysaccharide is a treasure house rich in magnesium element. Research shows that the magnesium intake can prevent and treat cardiovascular diseases and protect the inner cortex of arteries and blood vessels. Furthermore, the kudzu root has the main functions: dilating blood vessels; the pueraria flavonid and puerarin in the kudzuvine root can improve the oxygen metabolism of cardiac muscle, expand the blood vessel microcirculation, reduce the blood vessel resistance and increase the blood flow; the flavonoid can increase blood flow of brain and coronary blood vessel, puerarin can decrease coronary blood vessel resistance and increase coronary flow, and puerarin has obvious effect of lowering blood sugar. The Gynostemma pentaphyllum extract can prevent lipid deposition on vessel wall, improve immunity, and inhibit adverse reaction caused by glucocorticoid. In addition, the content of enteromorpha polysaccharide, the content of kudzu vine root, the content of gynostemma pentaphylla, the content of hawthorn and the content of monascus enzyme are further limited, so that the effect of reducing blood fat is improved to the optimal level, the side effect is avoided, and human body tests of a disease prevention and control center prove that the enteromorpha polysaccharide compound auxiliary blood fat reducing health care product can be used as an auxiliary blood fat reducing medicine.
Detailed Description
An enteromorpha polysaccharide compound auxiliary blood fat reducing health care product is a capsule, a tablet or a granule, and consists of the following raw materials: 50-70 parts of enteromorpha polysaccharide extract, 10-15 parts of kudzu root extract, 5-10 parts of gynostemma pentaphylla extract, 5-10 parts of hawthorn extract and 10-15 parts of red yeast rice enzyme, wherein the parts of the raw materials are in parts by weight.
A preparation method of an enteromorpha polysaccharide compound health product for assisting in reducing blood fat comprises the following steps:
(1) respectively weighing 50-70 parts of enteromorpha polysaccharide extract, 10-15 parts of kudzu root extract, 5-10 parts of gynostemma pentaphylla extract, 5-10 parts of hawthorn extract and 10-15 parts of red yeast enzyme, and mixing to obtain a mixed raw material;
(2) and (4) forming, drying, packaging and inspecting the mixed raw materials to obtain a finished product.
The enteromorpha polysaccharide compound auxiliary blood fat reducing health-care product and the enteromorpha polysaccharide extract in the preparation method are prepared according to an enteromorpha polysaccharide extraction method disclosed in the application No. 201310028640.9 patent.
According to the preparation method of the enteromorpha polysaccharide compound auxiliary blood fat reducing health-care product, the mixed raw material obtained in the step (1) is subjected to the following 3 examples, and the test conditions of the 3 examples are specifically listed as follows (see table 2):
TABLE 2
Animal experiments are carried out on the enteromorpha polysaccharide compound auxiliary hypolipidemic health product mixed raw material obtained in 3 embodiments of the application, and the TC, TG and LDL-C values of rats in a blank control group, a model control group and a gastric perfusion test sample group are respectively measured, and specific results are listed as follows (see table 3, the blood collection object of the blank control group in the table 3 is a common rat fed with common feed, the blood collection object of the model control group is a rat fed with high-fat feed and not a gastric perfusion test sample, and the objects of the embodiments 1-3 are rats fed with high-fat feed and high-dose gastric perfusion test samples):
TABLE 3
The data in table 3 above are part of the data taken from numerous experiments performed by the inventors. As can be seen from Table 3, the TC, TG and LDL-C values of the rats in the gavage test sample groups of examples 1-3 were significantly decreased compared to the model control group, while the HDL-C value was significantly increased compared to the model control group. Therefore, the enteromorpha polysaccharide composite health product mixed raw material for assisting in reducing blood fat has the function of assisting in reducing blood fat.
In addition, the inventor sends the mixed raw materials of the enteromorpha polysaccharide compound auxiliary blood fat reducing health care product obtained in the example 1 to a disease prevention and control center of Fujian province for animal tests (registration and inspection acceptance number: health care and inspection key 13-0173 of Fujian disease control center, and report number: health care and inspection key 13-0173-3 of Fujian disease control center), and the inspection results are as follows (see the following table 4 in detail): after a mixed type hyperlipemia animal model is adopted and molded for 7 days, the values of serum cholesterol (TC), Triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) of a model control group are higher than those of a blank control group, the differences have statistical significance (P is less than 0.05), and the establishment of the model is judged. After the test sample is orally taken and gavage for 30 days, the TC, TG and LDL-C values of the model control group are higher than those of the blank control group, and the differences have statistical significance (P is less than 0.05); the TC and TG values of rats in the high-dose group (i.e. the gavage test sample group) are lower than those of the model control group, the differences are both statistically significant (P is less than 0.05), and the LDL-C values are compared with the model control group, and the differences are not statistically significant (P is more than 0.05). According to the judgment standard in the evaluation method of the auxiliary blood fat reducing function (State food and drug administration [2012] 107), the enteromorpha polysaccharide composite auxiliary blood fat reducing health care product mixed raw material is considered to have the function of auxiliary blood fat reduction.
Table 4. influence of mixed raw materials of enteromorpha polysaccharide compound auxiliary hypolipidemic health product on rat blood fat (mmol/L, n is 10)
The inventor sends the enteromorpha polysaccharide compound auxiliary blood fat reducing health-care product which is prepared by the preparation method of the enteromorpha polysaccharide compound auxiliary blood fat reducing health-care product and has the same formula as the mixed raw material of the enteromorpha polysaccharide compound auxiliary blood fat reducing health-care product to a Shandong province disease prevention and control center for human body test (sample number: GZ03920140305), and the test results are as follows: adopting self and group control method, 102 hyperlipidemia subjects, 51 test-eating groups and 51 control groups. During the test eating period, the diet and living habits are not changed, the test sample is taken by the test eating group, the blank control is adopted by the control group, and the test sample and the control group are continuously taken for 60 days. After the test meal, the serum cholesterol (TC) is reduced by 0.51 +/-0.39 mmol/L compared with that before the test meal, and the difference is significant (P is less than 0.01); triglyceride (TG) is reduced by 0.28 +/-0.19 mmol/L, and the difference is significant (P is less than 0.01); the low-density lipoprotein cholesterol (LDL-C) is reduced by 0.19 +/-0.18 mmol/L, and the difference is significant (P is less than 0.01); after the TC and TG two indexes are eaten on test, the difference between the test group and the control group is obviously reduced (P is less than 0.01), and after the LDL-C test is eaten on test, the difference between the test group and the control group is obviously reduced (P is less than 0.01); the total effective rate of the test group is obviously higher than that of a control group (P is less than 0.01), and the test structure shows that the test substance has the function of assisting in reducing blood fat. After eating, blood, urine and stool routine and the examination of various safety indexes such as serum total protein, albumin, glutamic-oxaloacetic transaminase, glutamic-pyruvic transaminase, urea nitrogen, creatinine, uric acid, blood sugar and the like. The subjects were all in the normal range, indicating that the subjects had no adverse effect on the physical health of the test feeders. The general conditions (including spirit, sleep, diet, weight, stool and urine, blood pressure, heart rate and the like) are normal in the process of eating the test food, and no allergy or other adverse reactions are observed.
Certainly, the enteromorpha polysaccharide extract in the enteromorpha polysaccharide compound auxiliary blood fat reducing health-care product and the preparation method is also limited to be prepared according to the enteromorpha polysaccharide extraction method disclosed in the application No. 201310028640.9 patent.
Claims (2)
1. An enteromorpha polysaccharide compound auxiliary blood fat reducing health care product which is a capsule, a tablet or a granule, and is characterized in that: the health product comprises the following raw materials: 50-70 parts of enteromorpha polysaccharide extract, 10-15 parts of kudzu root extract, 5-10 parts of gynostemma pentaphylla extract, 5-10 parts of hawthorn extract and 10-15 parts of red yeast rice enzyme, wherein the parts of the raw materials are in parts by weight.
2. The preparation method of the enteromorpha polysaccharide compound auxiliary blood fat reducing health-care product according to claim 1 is characterized by comprising the following steps:
(1) respectively weighing 50-70 parts of enteromorpha polysaccharide extract, 10-15 parts of kudzu root extract, 5-10 parts of gynostemma pentaphylla extract, 5-10 parts of hawthorn extract and 10-15 parts of red yeast enzyme, and mixing to obtain a mixed raw material;
(2) and (4) forming, drying, packaging and inspecting the mixed raw materials to obtain a finished product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/107271 WO2019100843A1 (en) | 2017-08-17 | 2018-09-25 | Enteromorpha prolifera polysaccharide composite blood lipid-lowering health care product and preparation method therefor |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710705498 | 2017-08-17 | ||
| CN2017107054985 | 2017-08-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107669763A CN107669763A (en) | 2018-02-09 |
| CN107669763B true CN107669763B (en) | 2021-01-19 |
Family
ID=61149071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711187356.0A Active CN107669763B (en) | 2017-08-17 | 2017-11-24 | Enteromorpha polysaccharide compound auxiliary blood fat reducing health-care product and preparation method thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN107669763B (en) |
| WO (1) | WO2019100843A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107669763B (en) * | 2017-08-17 | 2021-01-19 | 福建海兴保健食品有限公司 | Enteromorpha polysaccharide compound auxiliary blood fat reducing health-care product and preparation method thereof |
| CN113559114B (en) * | 2021-09-26 | 2022-01-18 | 汇泰渤海水产有限责任公司 | Application of enteromorpha polysaccharide in reducing foam cell lipid accumulation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101518595A (en) * | 2008-02-28 | 2009-09-02 | 北京中泰天和科技有限公司 | Medical composition with functions of lowering lipid, reducing fat and oxidation resistance and preparation method thereof |
| CN101731599A (en) * | 2008-11-12 | 2010-06-16 | 柯宏 | Composition for preventing and treating cardiovascular and cerebrovascular diseases |
| CN103044570B (en) * | 2013-01-25 | 2015-08-26 | 福建海兴保健食品有限公司 | A kind of extraction process of high efficiency extraction sea grass polysaccharide |
| CN104068302A (en) * | 2013-03-29 | 2014-10-01 | 烟台大学 | Enteromorpha polysaccharide oral liquid and preparation method thereof |
| CN105726628A (en) * | 2016-03-30 | 2016-07-06 | 福建农林大学 | Compound enteromorpha polysaccharide composition with anti-EV71 virus effect |
| CN107669763B (en) * | 2017-08-17 | 2021-01-19 | 福建海兴保健食品有限公司 | Enteromorpha polysaccharide compound auxiliary blood fat reducing health-care product and preparation method thereof |
-
2017
- 2017-11-24 CN CN201711187356.0A patent/CN107669763B/en active Active
-
2018
- 2018-09-25 WO PCT/CN2018/107271 patent/WO2019100843A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019100843A1 (en) | 2019-05-31 |
| CN107669763A (en) | 2018-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100435663C (en) | Health-care food with functions of improving immunocompetence and protecting damaged gastric mucosa and its preparing method | |
| CN101822749B (en) | Medicinal preparation for curing hypertension and hyperlipaemia and preparation method thereof | |
| CN102406860A (en) | Composition for preventing and treating diabetes, and preparation method and use thereof | |
| CN101878906B (en) | Health care food with auxiliary hyperglycemic function and preparation method thereof | |
| CN101637491B (en) | Health-care food having functions of assisting antidiabetics and assisting antiatheroscloresis, and preparation method thereof | |
| CN106074971A (en) | A kind of hypoglycemic traditional Chinese medicine composition and preparation method and application | |
| CN100420391C (en) | Health-care food with anti-oxidation and lowering weight functions | |
| CN101869283A (en) | Assistant hypoglycemia healthcare food of mulberry-leaf extract and preparation method thereof | |
| CN109123612A (en) | A kind of composition with strengthen immunity, health food and preparation method thereof | |
| CN102551065A (en) | Blood sugar reducing food series | |
| CN107669763B (en) | Enteromorpha polysaccharide compound auxiliary blood fat reducing health-care product and preparation method thereof | |
| CN110074243A (en) | It is a kind of with relieving the effect of alcohol and protect the pressed candy of liver function | |
| CN101356975B (en) | Health food capable of increasing human immunity and promoting intelligence and strengthening brain and preparation method thereof | |
| CN108783461A (en) | Ultrasonic wave added/combined-enzyme method synchronizes the method for extraction coix seed active constituent and its preparation method and application of microemulsion | |
| CN100531783C (en) | Health-care food for reducing blood sugar on the assistant role and its preparing process | |
| CN102578451A (en) | Health-care food composite capable of decreasing blood sugar | |
| CN102885305A (en) | Health food composition for enhancing immunity and preparation method thereof | |
| CN101530209A (en) | A health-care food capable of adjusting blood fat and protecting liver and preparation method thereof | |
| CN102178718A (en) | Preparation used for treating diabetes mellitus and preventively treating heart cerebrovascular disease | |
| CN102048132B (en) | Health-care food for reducing blood sugar | |
| CN101450174A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN105360787A (en) | Health food and preparation method thereof | |
| CN103704691B (en) | A kind of natto propolis ginkgo leaf health food and preparation method thereof | |
| CN117770446A (en) | Nutritional composition for promoting recovery after exercise and preparation method and application thereof | |
| CN101450096A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |